In:
International Journal of Cancer, Wiley, Vol. 143, No. 8 ( 2018-10-15), p. 2039-2052
Abstract:
What's new? Mobilization of dendritic cells enhances tumor‐specific T cell responses but negative immune regulatory molecules, such as indoleamine 2,3‐oxygenase (IDO) attenuate dendritic cell‐mediated immunotherapy. Here the authors use simultaneous dendritic cell mobilization and IDO gene silencing via a dendritic cell–targeted siRNA delivery nanosystem to induce robust anti‐lung cancer immunity in vivo. This provides first proof‐of concept that a two‐pronged immunotherapy involving dendritic cells could be clinically relevant for patients with lung cancer.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink